Cost per month of overall survival and progression-free survival: everolimus compared with cabozantinib, nivolumab, and axitinib for metastatic renal cell carcinoma
BJU INTERNATIONAL（2016）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined